9 Meters Biopharma, Inc. (2Q3A.F)

0,0123 0,0000 (0,00%) Börsenschluss: 02:20PM CEST

9 Meters Biopharma, Inc.

4509 Creedmoor Road
Suite 201
Raleigh, NC 27612
United States
919 275 1933
https://www.9meters.com

Sektor(en): 
Branche: 
Vollzeitmitarbeiter: 10

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Peter H. R. Green M.D.	Clinical & Scientific Advisor and Consultant	N/A	N/A	N/A
Mr. Joseph A. Murray M.D.	Clinical & Scientific Advisor and Consultant	N/A	N/A	N/A
Dr. Ciaran P. Kelly M.D.	Clinical & Scientific Advisor and Consultant	N/A	N/A	N/A
Dr. Elena Verdu M.D., Ph.D.	Clinical & Scientific Advisor and Consultant	N/A	N/A	N/A
Mr. Markku Mäki M.D., Ph.D.	Clinical & Scientific Advisor and Consultant	N/A	N/A	N/A
Dr. William J. Sandborn M.D., Ph.D.	Clinical & Scientific Advisor and Consultant	N/A	N/A	1963
Dr. Roger Liddle M.D.	Clinical & Scientific Advisor and Consultant	N/A	N/A	N/A
Dr. Anthony J. Dimarino Jr.	Clinical & Scientific Advisor and Consultant	N/A	N/A	N/A
Dr. Brian Gordon Feagan FRCPC, M.D., M.P.H.	Clinical & Scientific Advisor and Consultant	N/A	N/A	N/A
Dr. Aida Habtezion M.D., M.Sc.	Clinical & Scientific Advisor and Consultant	N/A	N/A	N/A

Die Beträge haben den Stand und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America. Its lead product candidate is Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 3 clinical trial to treat short bowel syndrome. The company is developing NM-136, a humanized monoclonal antibody for the treatment of obesity and obesity-related disorders; NM-102, a small molecule peptide to prevent antigens from trafficking into systemic circulation; and NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease. Its partnered product is Larazotide, an 8-amino acid peptide, which is in Phase 2 clinical trial for treatment of multi-system inflammatory syndrome. The company has licensing agreements with Amunix, MHS Care Innovation LLC, Alba Therapeutics Corporation, and EBRIS. 9 Meters Biopharma, Inc. is headquartered in Raleigh, North Carolina. On July 17, 2023, 9 Meters Biopharma, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Eastern District of North Carolina.

Corporate Governance

9 Meters Biopharma, Inc.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.